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A commentary on
Integrating electrodermal biofeedback into pharmacologic treatment of grand mal seizures
by Scrimali, T., Tomasello, D., and Sciuto, M. (2015). Front. Hum. Neurosci. 9:252. doi:
10.3389/fnhum.2015.00252
Thirty percent of patients with epilepsy experience seizures despite optimal anticonvulsant
drug treatment. Stress is frequently identified by patients with epilepsy as a precipitant of
seizures (Spector et al., 2000; Ferlisi and Shorvon, 2014). Patients also often report using
countermeasures to control the seizure onset. These are typically spontaneous and individualized
such as increasing arousal by walking, breathing, standing, focusing attention, changing way of
thinking, and more rarely inducing relaxation (Lee and No, 2005; Hether et al., 2013). In parallel,
behavioral and psychological interventions, complementing conventional therapeutic methods for
the management of epileptic seizures, have gained greater clinical attention over the past decade.
Among these, Biofeedback (BFK) represents a noninvasive biobehavioral treatment that enables a
patient to gain volitional control over a specific physiological process. BFK has already shown its
value when applied to patients with epilepsy (Sterman and Friar, 1972; Rockstroh et al., 1993; Nagai
et al., 2004a; Nagai, 2011; Micoulaud-Franchi et al., 2014a,b). Scrimali et al. (2015) have rightly
pointed out the potential usefulness of electrodermal biofeedback in the management of refractory
epilepsy. In a single case study, they report an effect of electrodermal activity (EDA) relaxation
biofeedback in reducing seizures in a patient treated for 2 years. This case study supports the
necessity to expand clinical armamentarium for treatment-resistant patients with few alternatives.
However, in this commentary we would like to specify that contrary to what it is claimed by
the authors, decreasing arousal, using relaxation biofeedback is not the method proposed by Nagai
et al. (2004a). On the contrary, these authors used a protocol based on increasing arousal. The
EDA biofeedback treatment designed by Nagai et al. (2004a) is aimed at increasing the tonic levels
of peripheral sympathetic arousal rather than at decreasing EDA level. In addition, these authors
(Scrimali et al., 2015) cite Nagai et al. (2004a) when they claim that “Grand Mal” seizures are
characterized by increased sympathetic arousal. However, there is nomention of such a relationship
in the paper of Nagai et al. that rather highlights an inverse relationship between sympathetic
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arousal and an electroencephalographic index of cortical arousal
that is linked with seizure activity.
The motivation for believing that EDA relaxation biofeedback
may be beneficial for patients with epilepsy comes is
understandable given the relationship between stress and
increased skin conductance level. It is known that stress and
anxiety are commonly reported triggers of seizures (Fenwick,
1991; Antebi and Bird, 1993; Spector et al., 2001; Nakken et al.,
2005; Petitmengin et al., 2006; Pinikahana and Dono, 2009).
Thus, inducing relaxation in order to reduce the impact of
stress has theoretical justification for patients with epileptic
seizure triggered by stress. EDA reflects the action of sympathetic
autonomic nerves on eccrine sweat glands and is a sensitive
indicator of central (involuntary and voluntary induced) changes
in arousal, associated with emotion, attention, and physical
activity (Neumann and Blanton, 1970). In fact, EDA can be
increased not only by stress, but also by preparation of and
engagement with intellectual activity, during emotion regulation
or even when experiencing happiness (Gross and Levenson,
1993; Reynaud et al., 2012). Moreover, regarding the relationship
between autonomic physiology and seizures in epilepsy, a state
of enhanced relaxation/low arousal can potentially worsen
seizures through lowering the seizure threshold (Nagai et al.,
2004b). The theoretical rational behind the development of EDA
biofeedback originated with a neurofeedback protocol focusing
on Slow Cortical Potentials (SCP), an index of thalamocortical
excitability. In SCP neurofeedback, patients are trained to reduce
and reverse the negative amplitude of SCPs (Kotchoubey et al.,
2001). This neurofeedback method has been shown to elicit
a significant decrease in seizure frequency (Rockstroh et al.,
1993) and can produce a sustained benefit that is apparent
ten years after the end of treatment (Strehl et al., 2014). The
amplitude of the Contingent Negative Variation (CNV) (a
task-evoked event-related potential considered as a SCP and
hence an index of cortical excitation) is greater during states of
reduced autonomic arousal (Nagai et al., 2004b, 2009). Peripheral
sympathetic activity (autonomic arousal), measured using EDA,
can be increased either involuntarily by aversive auditory
stimulation, or voluntarily by using biofeedback arousal. In both
cases, the increase is associated with a reduction in the amplitude
of the CNV. This observation indicated that the measures of
peripheral sympathetic activity and thalamocortical excitation
(as measured by the CNV) are inversely related (Nagai et al.,
2004b). This inverse relationship led to the theoretical proposal
that enhancing autonomic arousal may have a therapeutic use in
preventing or curtailing the onset of seizures.
Despite strong theoretical underpinnings there is little direct
knowledge about the neural mechanisms underlying EDA
biofeedback on seizure onset. Scrimali et al. (2015) suggest
that Nagai (2014) report that “EDA-biofeedback can improve
thalamocortical regulation of neural excitability across brain
networks as it focuses on the reduction of peripheral sympathetic
tone.” This reference to a Japanese article is inaccurate and
confuses the likely manner in which way the regulation occurs.
The thalamus certainly has an important role in generation
of the CNV (Elbert and Rockstroh, 1987). In a neuroimaging
study, CNV-related central neural brain activation was observed
to extend beyond thalamus and to engage midline cortices,
notably the supplementary motor area (SMA) and mid cingulate
(Nagai et al., 2004c). The magnitude of activity within these
regions correlated with CNV amplitude on a trial-by-trial
basis, suggesting these areas are involved in the generation
of CNV. Importantly, a set of related (but distinct) cortical
regions (including orbitofrontal and ventral prefrontal cortex,
anterior cingulate cortex, insula, and right parietal cortex) are
involved in the regulation of EDA and have direct projections
to thalamus (Critchley et al., 2000). Moreover, modulation of
EDA level using biofeedback exerts a specific regulatory effect on
orbital and ventral prefrontal activity (Nagai et al., 2004d). The
implication is that EDA arousal biofeedback may thus modulate
thalamocortical information flow and consequently enable the
volitional reducing seizures occurrence (Nagai, 2011).
As evidence of the clinical efficacy of EDA arousal biofeedback
in the management of epileptic seizures, Nagai et al. (2004a)
report amean reduction of seizures of about 50% in a biofeedback
treatment group, compared to no difference in seizure frequency
in a control group undergoing sham biofeedback. Moreover,
across the treatment group, there was a positive correlation
between the patients’ reduction in seizure frequency and the
degree of improvement observed over training sessions in their
performance of the biofeedback task. Similar results, notably
an improvement in psychometric measures of symptoms of
depression and negative affect, are reported in patients with
stress-triggered seizures (Micoulaud-Franchi et al., 2014b). This
suggests that EDA arousal biofeedback training is applicable to
stress-related epilepsy, though perhaps counterintuitive given
typical relationship between stress and increased sympathetic
arousal. In both cases, patients were taught to target the use
of strategies developed during the biofeedback training session
to target preictal and ictal periods when increasing arousal
can serve as a countermeasure to decrease the risk of seizure
onset. The study of Scrimali et al. raises the issue that patients
who report stress as main trigger factor, typically identify
increases in chronic stress, rather than acute stressors, as seizure
precipitants (Privitera et al., 2014). In this way, decreasing stress-
related autonomic arousal by relaxation in the interictal period
might be specifically helpful for chronic stress management and
correspondingly reduce the latent risk of seizures. In this way, the
Scrimali et al. report could represent an interesting alternative
approach for the use of biofeedback in epilepsy that must be
demonstrated in a larger cohort.
In conclusion, EDA biofeedback has great potential as a
non-pharmacological therapy for the management of refractory
epilepsy. The methodology is grounded on theory, and
on increasing knowledge regarding the underlying neural
mechanisms, and the approach deserves greater clinical
attention. There also remains a need for continuing clinical
research, such as the case study report by Scrimali et al.
(2015). Despite some inaccurate interpretations of findings
of published EDA biofeedback papers, the study of Scrimali
et al. rises the need to develop noninvasive biobehavioral
treatment that target specifically pré-ictal/ictal periods or
interical periods to manage efficiently patients with refractory
epilepsy. Further studies that will establish and consolidate
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the role of EDA biofeedback as a complementary therapy for
epilepsy should bring: (i) large well-controlled, randomized,
double-blind, and long-term evaluations studies, (ii) optimal
implementation and embedding of the training with the EDA
biofeedback sessions, (iii) the possibility of incorporation of
different forms of bioefeedback and neurofeedback. All these
different areas need to be underpinned by neurophysiological
rationales.
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